(Adnkronos) – “Switzerland has represented a fundamental element in the internationalization of the Bracco group and it is precisely here that we have just completed a second plant in Plan-les-Ouates, alongside the historic factory built in 1997. It’s called Hexagon and has required an investment of over 80 million euros”. Diana Bracco, president and CEO of the homonymous pharmaceutical chemistry group, tells ‘Sole24Ore’.
The new plant, she explains, produces “an innovative ultrasound contrast agent, based on microbubbles that allows real-time diagnosis and is the still unsurpassed forerunner of all modern ultrasound contrast agents, used in millions of procedures every year. With the new site we will triple our production of an increasingly used modality worldwide, also because it is less invasive for patients and less expensive for health services. Hexagon is among the most futuristic plants of the group due to the high technological and digital content that is present in the control of both qualitative and quantitative processes, as well as in the alerts. Right here, the contiguity between the research center and production has allowed us to develop a platform that is giving us great satisfaction. Innovation is part of our DNA”, says the CEO.
As for the geopolitical situation, Bracco says, “this new investment we have made is a strong message for the country and for the sector. It is the sign of our willingness to continue investing, overcoming even the fear and uncertainty that the geopolitical context generates. We are a family-owned multinational with a historic brand that is approaching 100 years old and that continues to invest both in Italy and abroad. We represent Made in Italy in a very advanced sector”, she explains.
